Ramon Torres, M.D.

The question of how effective the repopulation of CD4 lymphocytes is in the prevention of reactivation of opportunistic infections in patients with advanced AIDS who have been placed on highly active antiretroviral therapy (HAART) was addressed by a ...

A new anti-CMV agent manufactered by Bristol Myers Squibb, Inc. was presented at the 4th National Conference on Retroviruses and Opportunistic Infections. Lobucavir is a cyclobutyl analog of guanine with broad spectrum antiviral activity against most...